Form 4: Aclaris Therapeutics Director Andrew Schiff Trades Shares

Aclaris Therapeutics Director Andrew Schiff reported transactions involving common stock, stock options, and restricted stock units.

Summary

• Andrew N. Schiff, a Director at Aclaris Therapeutics, Inc. (ACRS), reported several transactions on June 5, 2026.
• These transactions include the acquisition of 11,580 shares of common stock and the disposal of 434,455 shares.
• Additionally, Schiff was granted a stock option for 42,350 shares with an exercise price of $4.71, vesting monthly starting July 4, 2026.
• He also received 10,987 restricted stock units (RSUs) that vest on June 4, 2027, and 11,580 RSUs that vested on June 5, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider transactions including both acquisitions and disposals of securities, without clear indications of significant positive or negative strategic shifts.

Positives

• Director Andrew Schiff acquired 11,580 shares of common stock.
• Director Andrew Schiff was granted a stock option for 42,350 shares.
• Director Andrew Schiff received 10,987 restricted stock units vesting in the future.
• Director Andrew Schiff received 11,580 restricted stock units that have vested.

Negatives

• Director Andrew Schiff disposed of 434,455 shares of common stock.

Future Outlook

The filing details stock option grants and restricted stock units with future vesting dates, indicating ongoing equity-based compensation and potential future share ownership for the director.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and trading activities of company directors and officers. These filings are crucial for investors to understand insider sentiment and potential shifts in beneficial ownership.

Stakeholder Impact

• Shareholders: The disposal of a significant number of shares by a director may be interpreted in various ways, potentially influencing market perception. The acquisition of shares and grants of options/RSUs suggest continued commitment.
• Management: The transactions reflect standard compensation and equity management practices for directors.

Next Steps

• Vesting of stock options commencing July 4, 2026.
• Vesting of restricted stock units on June 4, 2027.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Transactions, Beneficial Ownership